NCT07144345 2026-03-05
Study of Reformulated Levulan Kerastick Plus PDT for Actinic Keratosis on Face and Scalp
Sun Pharmaceutical Industries Limited
Phase 3 Active not recruiting
Clinical Trials
68 trialsNCT07144852 2026-02-20
Study of Reformulated Levulan Kerastick Plus PDT for Actinic Keratosis on Upper Extremities
Sun Pharmaceutical Industries Limited
Phase 3 Active not recruiting
NCT05662202 2026-02-19
Study to Evaluate the Safety, Tolerability and Efficacy of BF-200 ALA (Ameluz®) in the Field-directed Treatment of Actinic Keratosis (AK) on the Extremities and Neck/Trunk With Photodynamic Therapy (PDT) Using a RhodoLED Lamp
Biofrontera Inc.
Phase 3 Active not recruiting
NCT05212246 2026-01-22
B3C
VA Office of Research and Development
Phase 3 Not yet recruiting
NCT06135415 2026-01-22
TirbAKare
Almirall, S.A.
Phase 3 Completed
NCT07273656 2025-12-09
TIRBACRYO
University Hospital, Lille
Phase 3 Not yet recruiting
NCT07137819 2025-08-22
EXACT-1
Aresus Pharma GmbH
Phase 3 Recruiting
NCT00472459 2025-04-18
Photodynamic Therapy (PDT) With Metvix® 160 Milligrams/Gram Cream in Organ Transplant Participants With Non-melanoma Skin Cancer
Galderma R&D
Phase 3 Completed
NCT02549352 2025-03-13
Efficacy and Safety of LEO 43204 in Field Treatment of Actinic Keratosis on Balding Scalp Including 12-month Follow-up
LEO Pharma
Phase 3 Completed
NCT03115476 2025-03-11
A Trial to Compare the Incidence of Squamous Cell Carcinoma (SCC) and Other Skin Neoplasia on Skin Areas Treated With Ingenol Disoxate Gel or Vehicle Gel for Actinic Keratosis on Face and Chest or Scalp
LEO Pharma
Phase 3 Terminated
NCT01541553 2025-03-10
A Sequential Treatment Regimen of Cryotherapy and Picato® for the Treatment of Actinic Keratosis on the Face and Scalp
LEO Pharma
Phase 3 Completed
NCT02361216 2025-03-10
Efficacy and Safety of Ingenol Mebutate Gel for Actinic Keratosis Applied on Large Area on Face, Scalp or Chest
LEO Pharma
Phase 3 Completed
NCT02547233 2025-03-10
Efficacy and Safety of LEO 43204 in Field Treatment of Actinic Keratosis on Face or Chest Including 12-month Follow-up
LEO Pharma
Phase 3 Completed
NCT02547363 2025-03-10
Efficacy and Safety of LEO 43204 in Field Treatment of Actinic Keratosis on Balding Scalp Including 12-month Follow-up
LEO Pharma
Phase 3 Completed
NCT02549339 2025-03-10
Efficacy and Safety of LEO 43204 in the Field Treatment of Actinic Keratosis on Face or Chest including12-month Follow-up
LEO Pharma
Phase 3 Completed
NCT01787383 2025-02-24
A Simultaneous Treatment Regimen Compared to a Sequential Treatment Regimen With Ingenol Mebutate Gel 0.015% and 0.05% of Two Areas With Actinic Keratosis on Face/Scalp and Trunk/Extremities
LEO Pharma
Phase 3 Completed
NCT05231044 2024-04-19
A Multi-Center Study to Evaluate the Efficacy and Safety of KX01 Ointment 1% on Actinic Keratosis on Face or Scalp
PharmaEssentia
Phase 3 Completed
NCT04552327 2024-03-05
KOHDIAK
Infectopharm Arzneimittel GmbH
Phase 3 Completed
NCT05279131 2024-01-23
A Study to Evaluate the Safety and Tolerability of Tirbanibulin Ointment 1% in Adult Participants With Actinic Keratosis
Almirall, S.A.
Phase 3 Completed
NCT02124733 2023-10-10
Protocols for Painless Photodynamic Therapy (PDT) of Actinic Keratoses
The Cleveland Clinic
Phase 3 Completed
NCT04269395 2023-10-10
A Study to Assess Recurrence of Actinic Keratosis in Participants Treated With Methyl Aminolevulinate Hydrochloride Cream or Vehicle Cream Who Achieved Complete Response to Treated Lesions in Earlier Study
Galderma R&D
Phase 3 Terminated
NCT01966120 2023-07-28
Safety and Efficacy Study for the Field-directed Treatment of Actinic Keratosis (AK) With Photodynamic Therapy (PDT)
Biofrontera Bioscience GmbH
Phase 3 Completed
NCT00304239 2023-07-03
Metvix PDT Versus Vehicle PDT With Aktilite CL128 Lamp in Patients With Actinic Keratosis on the Face and Scalp
Galderma R&D
Phase 3 Completed
NCT05078827 2023-03-14
Therapeutic Equivalence of Fluorouracil Cream, 5% Compared With Fluorouracil 5% Topical Cream of MylanPharmaceuticals Inc., U.S.A in the Treatment of Actinic Keratosis
Encube Ethicals Pvt. Ltd.
Phase 3 Completed
NCT04085367 2022-04-01
Multicenter Study to Assess the Efficacy and Safety of Methyl Aminolevulinate Hydrochloride (MAL) 16.8% Cream (CD06809-41) Versus Vehicle Cream for Actinic Keratosis of the Face
Galderma R&D
Phase 3 Completed
NCT01525329 2022-03-15
Combination Therapy With 5-Fluorouracil and Photodynamic Therapy in Post-transplant Premalignant Skin Disease
The Cleveland Clinic
Phase 3 Terminated
NCT00294320 2022-02-07
Evaluation of Two Different Non-invasive Techniques to Monitor the Clearance of Actinic Keratosis Lesions
Viatris Inc.
Phase 3 Completed
NCT02385318 2021-11-02
To Compare Safety and Efficacy of Perrigo's Drug Product Compared to an FDA Approved Drug Product in the Treatment of Actinic Keratosis
Padagis LLC
Phase 3 Completed
NCT02459795 2021-11-02
To Compare Safety and Efficacy of Perrigo's Drug Compared to an FDA Approved Drug in the Treatment of Actinic Keratosis
Padagis LLC
Phase 3 Completed
NCT03285477 2021-04-13
AK003
Almirall, S.A.
Phase 3 Completed
NCT00306800 2021-02-18
Metvix PDT Versus Vehicle PDT With Aktilite CL128 Lamp in Patients With Actinic Keratosis on the Face and Scalp
Galderma R&D
Phase 3 Completed
NCT01475071 2021-02-18
CoMet
Galderma R&D
Phase 3 Completed
NCT01686152 2020-11-24
Study Comparing Imiquimod Cream, 3.75% to Zyclara® (Imiquimod) Cream, 3.75% in the Treatment of Actinic Keratosis
Teva Pharmaceuticals USA
Phase 3 Completed
NCT00948428 2020-09-04
Bioequivalence of Generic Imiquimod Cream, 5% When Compared to Aldara™ (Imiquimod) Cream, 5% in the Treatment of Actinic Keratosis
Actavis Inc.
Phase 3 Completed
NCT01962987 2020-07-20
A Study Comparing Diclofenac Sodium Gel 3% to Solaraze® (Diclofenac Sodium) Gel 3% in the Treatment of Actinic Keratosis
Actavis Inc.
Phase 3 Completed
NCT02654769 2020-05-12
A Study of Equivalence of Generic Ingenol Mebutate Gel 0.05% and Picato Gel 0.05% in Subjects With Actinic Keratosis
Actavis Inc.
Phase 3 Completed
NCT03727074 2020-03-18
Bioequivalence Study to Compare Sol-Gel Technologies' 5-FU Cream With Efudex® (5-FU) Cream
Sol-Gel Technologies, Ltd.
Phase 3 Completed
NCT03200912 2020-01-14
An Equivalence Study of Generic Ingenol Mebutate Gel 0.015% and Picato Gel 0.015% in Subjects With Actinic Keratosis
Actavis Inc.
Phase 3 Completed
NCT02952898 2020-01-07
Study Comparing GDC 695 and Diclofenac Sodium Gel, 3% in Subjects With Actinic Keratoses
Balmoral Medical company
Phase 3 Completed
NCT02120898 2019-12-13
A Study to Evaluate the Safety and Efficacy Imiquimod Cream, 2.5% in Participants With Actinic Keratoses
Actavis Inc.
Phase 3 Completed
NCT02616601 2019-07-17
Multicenter, Double-blind, Placebo Controlled Comparing Test Fluorouracil Cream to Carac Cream in Actinic Keratosis
Actavis Inc.
Phase 3 Completed
NCT03826550 2019-02-01
Therapeutic Equivalence of Diclofenac Sodium Gel 3% vs Solaraze ® in the Treatment of Actinic Keratosis
Encube Ethicals Pvt. Ltd.
Phase 3 Completed
NCT03037541 2018-08-29
Cryosurgery and Cream Combination for Actinic Keratosis
Wake Forest University Health Sciences
Phase 3 Completed
NCT02473848 2018-07-19
IMOT001
University of Zurich
Phase 3 Terminated
NCT01459393 2017-06-28
Comparison Between 5-aminolevulinic Acid Photodynamic Therapy Versus Cryotherapy for Actinic Keratosis Treatment
Barretos Cancer Hospital
Phase 3 Completed
NCT02611804 2017-05-05
A Randomized, Double-Blind, Parallel-Group, Vehicle-Controlled, Multicenter Study Comparing Diclofenac Sodium Gel, 3% to Solaraze® Gel, 3% in the Treatment of Actinic Keratosis on the Face or Bald Scalp
Teva Pharmaceuticals USA
Phase 3 Completed
NCT02799069 2017-04-28
Evaluation of Safety and Efficacy of BF-200 ALA for the Treatment of Actinic Keratosis With Photodynamic Therapy
Biofrontera Bioscience GmbH
Phase 3 Completed
NCT02289768 2016-08-05
Study To Evaluate The Efficacy And Safety Of Actikerall® Solution In Patients With Grade I-II Actinic Keratoses
Almirall, S.A.
Phase 3 Completed
NCT01493921 2016-02-19
Efficacy Study & Safety Evaluation of SR-T100 Gel in Actinic Keratosis Treatment
G&E Herbal Biotechnology Co., LTD
Phase 3 Completed
NCT01532453 2016-01-08
Prevention of UV-induced Carcinogenic Skin Alterations in Immunosuppressed Solid Organ Transplanted Patients
Spirig Pharma Ltd.
Phase 3 Terminated